locoregionally advanced nasopharyngeal carcinoma: Induction chemotherapy with cisplatin and 5-fluorouracil followed by radiotherapy and concurrent cisplatin - A phase II study

Oncology

Volumn 74, Issue 3-4, 2008, Pages 158-166

  Ferrari, D ^a   Chiesa, F ^b   Codeca C ^a   Calabrese, L ^b   Jereczek Fossa, B A ^b,d   Alterio, D ^b   Fiore, J ^a   Luciani, A ^a   Floriani, I ^c   Orecchia, R ^b,d   Foa, P ^a,d  

^a SAN PAOLO HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemoradiation; Cisplatin; Fluorouracil; Nasopharyngeal carcinoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; FUROSEMIDE; GABAPENTIN; GRANISETRON; MANNITOL;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DYSGEUSIA; DYSPHAGIA; EPITHELIAL ULCER; ERYTHEMA; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FIBROSIS; FOLLOW UP; HUMAN; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NAUSEA; NECK FIBROSIS; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORAL ERYTHEMA; OROPHARYNGEAL MUCOSITIS; PERCEPTION DEAFNESS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RADIATION DOSE; SIDE EFFECT; SKIN TOXICITY; SPEECH DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 49549101365     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000151363     Document Type: Article

References (42)

1. Micheli A, Francisci S, Krogh V, Rossi AG, Crosignani P: Cancer prevalence in Italian cancer registry areas: the ITAPREVAL study. ITAPREVAL Working Group. Tumori 1999;85:309-369.
2. Berrino F, Capocaccia R, Coleman MP, Estève J, Gatta G, Hakulinen T, Micheli A, Sant M, Verdecchia A: Survival of cancer patients in Europe: the EUROCARE-3 study. Ann Oncol 2003;14(suppl 5):v128-v149.
3. World Health Organization. International Histological Classification of Tumours. Histological Typing of Tumours of the Upper Respiratory Tract and Ear, ed 2. Berlin, Springer, 1991.
4. Heng DM, Wee J, Fong KW, et al: Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. Cancer 1999;86:1912-1920.
5. Sanguineti G, Geara FB, Garden AS, Tucker SL, Ang KK, Morrison WH, Peters LJ: Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys 1997;37:985-996.
6. Qin DX, Hu YH, Yan JH, et al:Analysis of 1379 patients with nasopharyngeal carcinoma treated by radiation. Cancer 1988;61:1117-1124.
7. Ma J, Mai H, Hong M, et al: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1350-1357.
8. Huncharek M, Kupelnick B: Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol 2002;25:219-223.
9. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ: The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a metaanalysis of the published literature. J Clin Oncol 2004;22:4604-4612.
10. Baujat B, Audry H, Bourhis J, et al: Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data metaanalysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys 2006;64:47-56.
11. Chua DT, Ma J, Sham JS: Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2004;22:5524.
12. Al-Sarraf M, LeBlanc M, Giri PG, et al: Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol 1998;16:1310-1317.
13. Wee J, Tan EH, Tai BC, et al: Randomized trial of radiotherapy versus concurrent chemo-radiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738.
14. Roussy IG: Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs radiotherapy alone in stage IV (> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group VUMCA I Trial. Int J Radiat Oncol Biol Phys 1996;35:463-469.
15. Ma J, Mai HQ, Hong MH, et al: Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol 2001;19:1350-1357.
16. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, Clayman GL, Goepfert H, Peters LJ, Hong WK: Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. Cancer 1997;79:1279-1286.
17. Chan ATC, Teo PM, Leung TW, et al: A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995;33:569-577.
18. Chua DT, Sham JS, Choy D, et al: Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Asian-Oceanian Clinical Oncology Association Nasopharynx Cancer Study Group. Cancer 1998;83:2270-2283.
19. Hareyama M, Sakata K, Shirato H, et al: A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002;94:2217-2223.
20. Rischin D, Corry J, Smith J: Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol 2002;20:1845-1852.
21. Oh JL, Vokes EE, Kies MS: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564-569.
22. Al-Amro A, Al Rajhi N, Khafaga Y, et al: Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:508-513.
23. American Joint Committee on Cancer: Manual for Staging of Cancer, ed 5. Philadelphia, JB Lippincott, 1997.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
25. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Offset Publication, 1979.
26. National Cancer Institute: Common Toxicity Criteria Manual, Version 2.0. Bethesda, National Cancer Institute, 1999.
27. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
28. Low WK, Toh ST, Wee J, Fook-Chong SM, Wang DJ: Sensorineural hearing loss after radiotherapy and chemoradiotherapy: a single, blinded, randomized study. J Clin Oncol 2006;24:1904-1909.
29. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O'Sullivan B, Pang ES, O SK, Au GK, Lau JT: Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol 2005;23:6966-6975.
30. Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, Morandi L, Zucali R, Pilotti S, Grandi C, et al: Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in localregional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol 1988;6:1401-1410.
31. Kraiphibul P, Atichartakarn V, Clongsusuek P, Kulapaditharom B, Ratanatharathorn V, Isarangkul W: Nasopharyngeal carcinoma: results of treatment by radiotherapy versus chemotherapy plus radiotherapy. J Med Assoc Thai 1991;74:391-396.
32. Lin JC, Jan JS, Hsu CY Liang WM, Jiang RS, Wang WY: Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;15:631-637.
33. Chan ATC, Teo PM, Ngan RK, Leung TW, Lau WH, et al: Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-2044.
34. Ho JHC: An epidemiologic and clinical study of nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1978;4:183-205.
35. Chan ATC, Ma BBY, Lo D , Leung SF, Kwan WH, Hui EP, Mok TSK, Kam M, Chan LS, Chiu SKW, Yu KH, Cheung KY, Lai K, Lai M, Mo F, Yeo W, King A, Johnson PJ, Teo PML, Zee B: Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol 2004;22:3053-3060.
36. Gibson MK., Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, Forastiere AA: Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:3562-3567.
37. Altundag O, Gullu I, Altundag K, Yalcin S, Ozyar E, Cengiz M, Akyol F, Yucel T, Hosal S, Sozeri B: Induction chemotherapy with cisplatin and 5-fluorouracil followed by chemoradiotherapy or radiotherapy alone in the treatment of locoregionally advanced resectable cancers of the larynx and hypopharynx: results of a single-center study of 45 patients. Head Neck 2005;27:15-21.
38. Airoldi M, De Stefani A, Marchionatti S, Pedani F, Gabriele P, Ragona R, Cortesina G, Bumma C: Survival in patients with recurrent squamous cell head and neck carcinoma treated with bio-chemotherapy. Head Neck 2001;23:298-304.
39. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-1128.
40. Kurek R, Kalogera-Fountzila A, Muskalla K, Dafni U, Schnabel T, Kober B, Roddiger S, Martin T, Fountzilas G, Zamboglu N: Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Onkol 2003;179:292-297.
41. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre J-L, the EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704.
42. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM, Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; the TAX 324 Study Group: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.